Viokase 16, Viokase16 Plus Nexium and Nexium Alone
Status:
Terminated
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
Our primary hypothesis is that the addition of Nexium to Viokase 16 will decrease the chronic
abdominal pain in patients with small duct chronic pancreatitis in a superior fashion
compared to Viokase 16 plus placebo or to Nexium alone. A secondary hypothesis would be an
increase in quality of life. Our objective is to elucidate the role of Nexium in the control
of pancreatic pain, quality of life, and narcotic usage alone or when added to Viokase 16.
Our endpoints are the reduction of abdominal pain, decreased pain medication usage, decreased
ER visits and decreased hospital admissions for abdominal pain.